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Exposure to hepatitis C virus (HCV) is frequently followed
by chronification. Contagion is more common through
following parenteral exposure (e.g., intravenous drug use)
than after sexual contacts. Since there is no protective
immunity against HCV, re-infection after spontaneous
HCV clearance accounts for a greater rate of chronicity in
IDUs compared to persons sexually exposed to HCV. Cur-
rent treatment of hepatitis C is based on the combination
of weekly subcutaneous pegylated interferon plus daily
oral ribavirin. Overall 75% of HIV patients infected with
genotypes 2 or 3 and around 40% of subjects infected
with genotypes 1 or 4 can achieve sustained virological
response, which means eradication of HCV. Patients with
known baseline serum HCV-RNA respond more than
those with high baseline HCV levels, regardless of HCV
genotype. The length of treatment must be adapted to
patient's features, being recommended to be for 6 months
in HCV genotypes 2/3 with low viremia and lack of cirrho-
sis, while it should be extended beyond 12 months in
HCV genotypes 1/4 with high baseline viremia or lack of
rapid virological response (negative serum HCV-RNA at
week 4 of treatment). High exposure to ribavirin is associ-
ated with higher antiviral effects; however, haemolytic
anemia is the most important limiting side-effect of riba-
virin and often precludes the use of high dosing. Adjuvant
weekly subcutaneous erythropoietin may help to manage
anemia in some situations. However, the PERICO trial has
shown that pre-emptive use of erythropoietin does not
enhance virological response rates, most likely due to
erythrocyte ribavirin sequestration. Due to inhibitory
competition in the phosphorylation pathway within the
cells as guanosine analogues, ribavirin should not be pre-
scribed along with abacavir. On the other hand, the use of
didanosine must be avoided along with ribavirin since
toxic didanosine metabolites are increased, with
enhanced risk of mitochondrial toxicities including lactic
acidosis, hepatic decompensation and pancreatitis. The
prospects for new specific anti-HCV agents are coming
slowly. HCV protease inhibitors (e.g. telaprevir), nucleo-
side analogs (e.g. R-1626), and four different classes of
non-nucleoside HCV polymerase inhibitors are rapidly
progressing in clinical development. Drug resistance in
HCV will be very challenging for most of these agents, and
accordingly, as in the HIV field, combination therapy is
the way to go on. Although the new drugs will be com-
bined with pegylated interferon and ribavirin in a first
moment, the prospects for combining new agents moving
off interferons are eagerly searched.
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